Kimberly Brown Dahlman, Ph.D.

Assistant Professor

kimberly.b.dahlman@vanderbilt.edu

Visit Lab Site


Faculty Appointments
Assistant Professor of Medicine
Education
Ph.D., Cancer Biology, Vanderbilt University, Nashville, TennesseeB.S., Lafayette College, Easton, Pennsylvania
Office Address
Vanderbilt University
771 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232
Research Description
The mission of the Innovative Translational Research Shared Resource (ITR) is to advance the translation of research into improved anti-cancer therapies. The ITR partners with oncologists and laboratory and non-laboratory investigators to guide, manage, and facilitate pre-clinical and clinical trial laboratory discoveries. Our broad experience in cancer clinical trials, genomics, biochemistry, and cell biology allows us to pursue unique research projects. We leverage ITR resources, other Vanderbilt Shared Resources, other academic institutions, and/or companies to achieve individual project goals. Since 2010, the ITR has collaborated with investigators in seven VICC research programs including Genome Maintenance, Signal Transduction and Chemical Biology, Host-Tumor Interactions, Cancer Health Outcomes and Control, Translational Research and Interventional Oncology, Gastrointestinal Cancer, and Breast Cancer.
Research Keywords
Cancer, Translational Research, Clinical Research
Publications
Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov [print-electronic]. 2017 Nov; 7(11): 1248-65. PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov [print-electronic]. 2017 Nov; 7(11): 1248-65. PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.

Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2017 Sep 9/20/2017; PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.

Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2017 Sep 9/20/2017; PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol [print-electronic]. 2017 Apr; 11(4): 405-21. PMID: 28188683, PMCID: PMC5378659, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261.

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol [print-electronic]. 2017 Apr; 11(4): 405-21. PMID: 28188683, PMCID: PMC5378659, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene [print-electronic]. 2016 Mar 3/10/2016; 35(10): 1225-35. PMID: 26073081, PMCID: PMC4679729, PII: onc2015188, DOI: 10.1038/onc.2015.188, ISSN: 1476-5594.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene [print-electronic]. 2016 Mar 3/10/2016; 35(10): 1225-35. PMID: 26073081, PMCID: PMC4679729, PII: onc2015188, DOI: 10.1038/onc.2015.188, ISSN: 1476-5594.

Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.

Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.

McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood [print-electronic]. 2015 Jul 7/23/2015; 126(4): 508-19. PMID: 26082451, PMCID: PMC4513251, PII: blood-2014-11-611194, DOI: 10.1182/blood-2014-11-611194, ISSN: 1528-0020.

McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood [print-electronic]. 2015 Jul 7/23/2015; 126(4): 508-19. PMID: 26082451, PMCID: PMC4513251, PII: blood-2014-11-611194, DOI: 10.1182/blood-2014-11-611194, ISSN: 1528-0020.

Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J. Am. Coll. Surg [print-electronic]. 2015 Apr; 220(4): 581-93.e1. PMID: 25797743, PII: S1072-7515(15)00074-5, DOI: 10.1016/j.jamcollsurg.2014.12.057, ISSN: 1879-1190.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.

Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther [print-electronic]. 2014 Jul; 13(7): 1918-28. PMID: 24755198, PMCID: PMC4090262, PII: 1535-7163.MCT-13-0804, DOI: 10.1158/1535-7163.MCT-13-0804, ISSN: 1538-8514.

Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther [print-electronic]. 2014 Jul; 13(7): 1918-28. PMID: 24755198, PMCID: PMC4090262, PII: 1535-7163.MCT-13-0804, DOI: 10.1158/1535-7163.MCT-13-0804, ISSN: 1538-8514.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.

Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.

Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res [print-electronic]. 2013 Sep; 23(9): 1434-45. PMID: 23733853, PMCID: PMC3759720, PII: gr.152322.112, DOI: 10.1101/gr.152322.112, ISSN: 1549-5469.

Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res [print-electronic]. 2013 Sep; 23(9): 1434-45. PMID: 23733853, PMCID: PMC3759720, PII: gr.152322.112, DOI: 10.1101/gr.152322.112, ISSN: 1549-5469.

Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013; 5(10): 91. PMID: 24112718, PMCID: PMC3971343, PII: gm495, DOI: 10.1186/gm495, ISSN: 1756-994X.

Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013; 5(10): 91. PMID: 24112718, PMCID: PMC3971343, PII: gm495, DOI: 10.1186/gm495, ISSN: 1756-994X.

Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov [print-electronic]. 2012 Sep; 2(9): 791-7. PMID: 22798288, PMCID: PMC3449158, PII: 2159-8290.CD-12-0097, DOI: 10.1158/2159-8290.CD-12-0097, ISSN: 2159-8290.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov [print-electronic]. 2012 May; 2(5): 414-24. PMID: 22588879, PMCID: PMC3594852, PII: 2159-8290.CD-12-0022, DOI: 10.1158/2159-8290.CD-12-0022, ISSN: 2159-8290.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res [print-electronic]. 2012 Apr 4/15/2012; 18(8): 2184-98. PMID: 22351689, PMCID: PMC3724517, PII: 1078-0432.CCR-11-1122, DOI: 10.1158/1078-0432.CCR-11-1122, ISSN: 1078-0432.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012; 3: 724. PMID: 22395615, PMCID: PMC3530385, PII: ncomms1727, DOI: 10.1038/ncomms1727, ISSN: 2041-1723.

Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE [print-electronic]. 2012; 7(4): e35309. PMID: 22536370, PMCID: PMC3335021, PII: PONE-D-12-03589, DOI: 10.1371/journal.pone.0035309, ISSN: 1932-6203.

Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS ONE [print-electronic]. 2012; 7(4): e34414. PMID: 22509301, PMCID: PMC3324507, PII: PONE-D-11-18538, DOI: 10.1371/journal.pone.0034414, ISSN: 1932-6203.

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Dec 12/15/2011; 480(7377): 387-90. PMID: 22113612, PMCID: PMC3266695, PII: nature10662, DOI: 10.1038/nature10662, ISSN: 1476-4687.

Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-¿B signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Mar 3/24/2011; 471(7339): 523-6. PMID: 21430781, PMCID: PMC3541675, PII: nature09870, DOI: 10.1038/nature09870, ISSN: 1476-4687.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010 Dec 12/14/2010; 18(6): 683-95. PMID: 21156289, PMCID: PMC3026446, PII: S1535-6108(10)00484-8, DOI: 10.1016/j.ccr.2010.11.023, ISSN: 1878-3686.

Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL. Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1. J. Cell. Biochem. 2008 Oct 10/1/2008; 105(2): 596-611. PMID: 18729074, PMCID: PMC2700048, DOI: 10.1002/jcb.21860, ISSN: 1097-4644.

Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem. 2007 May 5/1/2007; 101(1): 9-33. PMID: 17340614, DOI: 10.1002/jcb.21255, ISSN: 0730-2312.

Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol. Ther. 2007 Apr; 6(4): 561-70. PMID: 17495520, PMCID: PMC3395216, PII: 3851, ISSN: 1538-4047.

Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 2006 Aug 8/1/2006; 66(15): 7589-97. PMID: 16885358, PII: 66/15/7589, DOI: 10.1158/0008-5472.CAN-06-2020, ISSN: 0008-5472.

Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005 Jul 7/28/2005; 24(32): 5053-68. PMID: 15856015, PMCID: PMC3074577, PII: 1208685, DOI: 10.1038/sj.onc.1208685, ISSN: 0950-9232.

Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004 Sep; 6(5): 603-10. PMID: 15548370, PMCID: PMC1531665, DOI: 10.1593/neo.04241, ISSN: 1522-8002.

Brown K, Bhowmick NA. Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle [print-electronic]. 2004 Apr; 3(4): 408-10. PMID: 14752278, PII: 778, ISSN: 1538-4101.

Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res [print-electronic]. 2004; 6(3): R215-31. PMID: 15084245, PMCID: PMC400675, PII: bcr778, DOI: 10.1186/bcr778, ISSN: 1465-542X.

Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res [print-electronic]. 2004; 6(2): R130-9. PMID: 14979923, PMCID: PMC400660, PII: bcr762, DOI: 10.1186/bcr762, ISSN: 1465-542X.

Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2003 Dec 12/23/2003; 100(26): 15548-53. PMID: 14657354, PMCID: PMC307605, PII: 2536483100, DOI: 10.1073/pnas.2536483100, ISSN: 0027-8424.

Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997 Dec 12/18/1997; 241(2): 270-4. PMID: 9425261, PII: S0006-291X(97)97798-6, DOI: 10.1006/bbrc.1997.7798, ISSN: 0006-291X.